Sebacic Acid

Sebacic Acid

SCHEMBL7696353

CCC(Oc1ccccc1C(=O)O)Oc1ccccc1C(=O)O.O=C(O)CCCCCCCCC(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
RECQL P46063 1/20 0.54
ALDH1A1 P00352 7/20 0.47
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 6/20 0.45
HPGD P15428 4/20 0.45
PTGS2 P35354 2/20 0.44
ESR1 P03372 1/20 0.44
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44
HMGB1 P09429 1/20 0.44
TSHR P16473 1/20 0.44
GGT1 P19440 1/20 0.44
PTGS1 P23219 1/20 0.44
BLM P54132 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL554352 0.89 KDM4E (0.55) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL6836605 0.83 KDM4E (0.56) KDM4EKMT2AMEN1RECQLALDH1A1
Azelaic Acid SCHEMBL7892389 0.81 ALDH1A1 (0.56) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL28878425 0.79 KDM4E (0.72) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL9136787 0.79 KDM4E (0.72) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL974685 0.79 KDM4E (0.46) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL17309756 0.78 KDM4E (0.58) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL17309764 0.78 KDM4E (0.58) KDM4EKMT2AMEN1RECQLALDH1A1
Sebacic Acid SCHEMBL3897460 0.78 KMT2A (0.67) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL17309763 0.78 KDM4E (0.61) KDM4EKMT2AMEN1RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340501-B2 Marinopyrrole derivatives as anticancer agents H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2016-05-17 US disclosed
US-20150080632-A1 MARINOPYRROLE DERIVATIVES AS ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-19 US disclosed
US-6342051-B1 Treatment of anoxic tissue with angiogenesis-inducing implants VITROPHAGE, INC. 2002-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080632-A1 MARINOPYRROLE DERIVATIVES AS ANTICANCER AGENTS MAP2, MAP4, MDN1 KDM4E 2582/4885KMT2A 1823/4885MEN1 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.